Every decision in the OOTW Veterans Restoration Protocol — the compound, the dose, the cadence, the integration framework — is grounded in peer-reviewed clinical science from the world's leading research institutions. This is that science.
The OOTW Veterans Protocol was not built on intuition, tradition, or anecdote. It was built on a specific convergence of clinical evidence: neuroimaging studies showing what psilocybin does to the traumatized brain, controlled trials documenting measurable PTSD symptom reduction, and mechanistic research explaining why sub-perceptual dosing produces lasting neuroplastic change.
Every element of the protocol — the compound selection, the microdose calibration, the integration window timing, the Spirit Guide support infrastructure — maps to a specific body of scientific literature. When we say the protocol is science-backed, we mean that the decisions are traceable to specific peer-reviewed findings from specific institutions on specific patient populations.
This page is that traceability made visible. Every article below is a direct reference point for a specific aspect of what we do and why we do it. The science is not in dispute. The question is only whether we act on it quickly enough.
Modern research converges on five neurological mechanisms that explain why psilocybin microdosing works — and why conventional treatment cannot reach them.
Psilocybin triggers a 12× increase in dendritic spine density and BDNF upregulation within 24 hours of a session — physically rebuilding the neural infrastructure trauma degraded.
The Default Mode Network holds the self-narrative. In PTSD and moral injury, it holds the veteran to a narrative of damage. Psilocybin's 40% reduction in DMN connectivity loosens that lock.
Combat PTSD hyperactivates the amygdala into a state of constant threat detection. Psilocybin reduces amygdala reactivity and restores prefrontal inhibitory control — allowing response over reaction.
PTSD is not a memory problem — it is a fear extinction failure. Psilocybin restores the hippocampal neuroplasticity that allows the brain to contextualise past threat as past rather than present.
The 72-hour neuroplasticity window following a psilocybin session is when lasting transformation consolidates. The protocol is timed around this window to maximise structural change.
The foundational clinical science directly applicable to the veteran population — PTSD mechanisms, treatment trials, and combat trauma neuroscience.
From Battlefield to Breakthrough: Psilocybin-Assisted Therapy for Veterans
How psilocybin addresses the structural neurological damage of combat trauma and moral injury — three mechanisms rewriting the science of PTSD treatment. The foundational article for the OOTW protocol rationale.
80% of veterans in psilocybin trials report significant PTSD symptom reduction
Read Research → Clinical Research · FeaturedPsilocybin and PTSD: The Emerging Evidence
PTSD is not a memory problem — it is a fear extinction failure. The brain learned to fear and forgot how to unlearn. New clinical trials testing whether psilocybin can restore what trauma took away.
40% reduction in amygdala hyperreactivity to trauma cues (McGowan Phase 2, 2025)
Read Research →Peer-reviewed trials and published neuroscience on the specific conditions the OOTW protocol addresses: depression, anxiety, chronic pain, and grief.
Psilocybin and Depression: What Phase 3 Trials Actually Show
Phase 2b/3 clinical trials on psilocybin for depression. COMPASS, Imperial College, and Johns Hopkins data reviewed in full detail.
29% remission at 3 weeks vs 9% placebo (NEJM, Goodwin et al. 2022)
Read Research → AnxietyPsilocybin and Anxiety: The Neuroscience of Dissolving Fear
284 million people live with anxiety disorders. Most treatments fail half of patients. Then psilocybin produced 80% sustained relief after a single session.
80% sustained anxiety relief at 6-month follow-up (Griffiths et al., 2016)
Read Research → Pain SciencePsilocybin and Chronic Pain: Breaking the Pain Cycle
Chronic pain rewires the brain's default mode network the same way addiction does — and psilocybin may directly target that architecture. The emerging science of psychedelic analgesia.
50%+ attack frequency reduction in cluster headache patients (Yale, 2021)
Read Research → Grief & LossPsilocybin and Grief: The Neuroscience of Healing What Cannot Be Fixed
7–10% of bereaved people get trapped in a DMN loop antidepressants cannot reach. The complete neuroscience of psilocybin and prolonged grief disorder.
80% of cancer patients: clinically significant reductions sustained at 4.5-year follow-up
Read Research → Grief TherapyPsilocybin-Assisted Grief Therapy: Clinical Evidence for Healing Complicated Loss
Clinical trials show psilocybin-assisted therapy produces significant, lasting reductions in grief and prolonged grief disorder. The complete evidence base.
80% of patients showed clinically significant reductions at 6-month follow-up
Read Research → OCDPsilocybin and OCD: Interrupting the Loop
73.3% of OCD patients responded to psilocybin in a 2026 RCT. Three trials now point to the same mechanism: 5-HT2A activation in the cortex that drives the loop.
73.3% responder rate · 40% full remission (Moreno RCT, 2026)
Read Research →The specific peer-reviewed evidence behind our microdose calibration, dosing schedule, and protocol design decisions.
Microdosing Psilocybin: What the Science Actually Says
Sub-perceptual psilocybin doses are among the most widely practised yet least understood interventions in psychedelic medicine. The peer-reviewed evidence — including what it proves and what remains to be established.
Read Research → Dosing Science · Protocol FoundationMicro to Macro: The Science of Psilocybin Dosing Protocols
From microdose to full therapeutic session: a complete breakdown of psilocybin dosing protocols, what the clinical trials actually used, and how dose selection maps to therapeutic intention.
58% complete mystical experience rate at 30mg · 25mg standard clinical trial dose (Griffiths, 2016)
Read Research →The neuroplastic window following a psilocybin session is where transformation either consolidates or dissipates. Our protocol is structured around it.
Integration Science: The 72-Hour Neuroplasticity Window After Psilocybin
The session catalyzes. The 72-hour neuroplasticity window that follows — dendritic spine formation, BDNF elevation, synaptic remodeling — is where lasting transformation is built or lost. This is why the OOTW protocol includes structured integration support throughout.
+10% increase in prefrontal dendritic spine density within 24 hours, persistent at 1 month (Shao et al., Neuron 2021)
Read Research → Sleep SciencePsilocybin and Sleep Architecture: The Neuroscience of Deep Sleep Restoration
Insomnia, fractured REM, and suppressed slow-wave sleep all share a common upstream driver — and psilocybin targets it directly. The emerging neuroscience of psychedelic sleep restoration.
72% showed clinically significant sleep quality improvement after 2 psilocybin sessions (Davis et al., 2021)
Read Research →Combat trauma severs connection — to self, to others, to meaning. These articles cover the neuroscience of how psilocybin restores what isolation takes.
Oxytocin, Psilocybin, and the Neuroscience of Social Connection
Psilocybin activates oxytocin pathways, reshapes social perception, and produces measurable increases in empathy and connectedness. The complete neuroscience of why psychedelics make you feel more human.
58% increase in social-emotional responsiveness · increases in openness persisted at 14-month follow-up
Read Research → Moral InjuryThe Integration Challenge: Why Veterans Need More Than a Session
Military culture values stoicism and emotional suppression. The psilocybin experience demands the opposite. The OOTW integration framework is built specifically for this gap.
25–50% of combat veterans experience significant moral injury — distinct from, and compounding, PTSD
Read Full Article →Every element of the OOTW Veterans Restoration Protocol is grounded in the research above. 100% free for every veteran who enters. Fully funded by sponsors.